Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesLong-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children
Clinical and Translational Oncology, 06/30/09
Munoz A et al. - The therapeutic protocol achieved good oncologic and orthopaedic results. The authors observed a significant treatment-related toxicity.
Today in Bone/Cartilage...keeping you current
Receive free subspecialty "5-minute updates" via email
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient
International Journal of Clinical Oncology, 10/30/09
Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI
The Journal of Nuclear Medicine, 08/26/09
Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases
Journal of Clinical Oncology, 09/14/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the childrens oncology group
Journal of Clinical Oncology, 10/12/09
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 10/22/09
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09
Sponsor
Article Search
Sponsor
Sponsor